TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02007421

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Participants asked questions about recent experiences of anal intercourse in the last six months.
Description: Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Participants asked questions about recent experiences of anal intercourse in the last six months.
Description: Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.~At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy
Description: The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: High Resolution Anoscopy
Description: The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
Study: NCT04006652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ApoGraft
Description: ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
Study: NCT01726634

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Elastic Tapping
Study: NCT02187120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04135131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pilates mat exercises and home exercises
Description: Patients with low back pain were randomized into pilates (group 1) or home exercise group (group 2) 3 times/week for 8 weeks. Pilates mat exercise program comprised three sessions a week for 8 weeks (Monday, Wednesday, and Friday), with each session being scheduled for 1 h (5-min warm-up, 50-min exercise, and 5-min cooling) and each set comprising 10 repetitions. The home exercise program included the pelvic tilt in the supine position, hamstring stretch, hip flexors and lumbar extensor stretch, bridge, strengthening the abdominal muscles, cat/camel exercises in the crawl position, leaning on the forearms in the prone position, strengthening the back extensors, and crossed-arms/legs lift exercises.
Study: NCT02412267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)
Description: Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
Study: NCT03195413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided forearm nerve block
Description: An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine
Description: This is the anesthetic solution that will be administered during the ultrasound-guided nerve block

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bedside ultrasound machine
Description: This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
Study: NCT01747681

Intervention type: PROCEDURE
Intervention: Microfracture
Study: NCT03380429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.
Study: NCT01681082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi training
Description: 24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
Study: NCT02346565

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Exercise ECG

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Stress Echocardiography
Study: NCT02039531

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma rich in growth factors

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyaluronic Acid
Study: NCT04011475

Intervention type: DRUG
Intervention: Tiotropium + Olodaterol
Description: Spiolto®

Intervention type: DRUG
Intervention: Other LABA/LAMA
Description: tiotropium/olodaterol, indacaterol/glycopyrronium, vilanterol/umeclidinium

Intervention type: DRUG
Intervention: LAMA
Description: aclidinium bromide, glycopyrronium, tiotropium, umeclidinium
Study: NCT03380429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol
Description: Salbutamol will be available at a dose of 100 µg to be administered via MDI. Subjects will be administered salbutamol as and when required.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone app
Description: Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone app
Description: Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone app
Description: Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Smart phone app
Description: Subjects will be required to download an app associated with sensor on their smartphone. The sensors attached to the inhalers will be connected to the smartphone via Bluetooth.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCP Dashboard
Description: The information from sensors will be reviewed by the HCP via an online dashboard.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HCP Dashboard
Description: The information from sensors will be reviewed by the HCP via an online dashboard.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.
Study: NCT02595567

Intervention type: DEVICE
Group type: OTHER
Intervention: Indwelling tunneled pleural catheter (ITPC)
Description: ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
Study: NCT02184468

Intervention type: OTHER
Group type: OTHER
Intervention: Simultaneously dispatch of firefighters and/or police in case of OHCA
Description: In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
Study: NCT06367582

Intervention type: DEVICE
Intervention: Vertebroplasty (VP)
Description: Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Vertebroplasty (VP)
Description: Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Vertebroplasty (VP)
Description: Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Vertebroplasty (VP)
Description: Vertebroplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Kyphoplasty (KP)
Description: Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Kyphoplasty (KP)
Description: Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Kyphoplasty (KP)
Description: Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Kyphoplasty (KP)
Description: Kyphoplasty is a procedure in which a special medical-grade cement mixture is injected into a fractured vertebra to relieve pain

Intervention type: DEVICE
Intervention: Pedicular Screw Augmentation (PSA)
Description: Pedicular Screw Augmentation is a procedure in which a special medical-grade cement mixture is injected into pedicular screws in order to augment fixation strength
Study: NCT02098343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APR-246
Description: Intravenous infusion.
Study: NCT03490331

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP)
Description: Surgergical procedure for transplantation under anaesthesia of genetically corrected cultured epidermal autograft (Hologene17) on blistering skin areas of JEB patients. By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue - containing genetically modified stem cells - is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery.
Study: NCT02875431

Intervention type: PROCEDURE
Intervention: Patients undergo ACDF or cervical vertebral body replacement
Study: NCT03327532

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clinical examination centered on congestion
Description: Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cardio-pulmonary and peritoneal ultrasound
Description: Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
Study: NCT03380429

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sensors
Description: Clip-on sensors will be fitted to electronically record the actuation data.
Study: NCT02968602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline
Description: Minocycline capsules taken twice daily for two weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules taken twice daily for two weeks.
Study: NCT03160937

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual therapy
Description: The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual therapy
Description: The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
Study: NCT00126750

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: VA MI Plus Interactive
Description: The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
Study: NCT02647710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PHAT Life Intervention
Description: HIV Prevention behavioral health intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Promotion Control
Description: Behavioral health intervention control
Study: NCT02501122

Intervention type: OTHER
Intervention: Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database
Description: Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
Study: NCT02702128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Description: 1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline solution
Description: 30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
Study: NCT03211676

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Theranova-500 dialyzer
Description: hemodialysis with Theranova-500 dialyzer.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theranova-500 dialyzer
Description: hemodialysis with Theranova-500 dialyzer.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Elisio-21H
Description: hemodialysis with Elisio-21H dialyzer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elisio-21H
Description: hemodialysis with Elisio-21H dialyzer
Study: NCT04052217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile Ring
Description: Penile Ring at base of penis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile Ring
Description: Penile Ring at base of penis

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Penile Ring
Description: Penile Ring at base of penis

Intervention type: DEVICE
Group type: OTHER
Intervention: Penile Ring
Description: Penile Ring at base of penis
Study: NCT03298386

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systematic medication review with the STOPP/START tool
Description: The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
Study: NCT03327532

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blood sample retrieved for biological assessment and biobanking
Description: Blood sample collection will be performed within 72 hours of admission and before discharge from hospital

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone interview
Description: Telephone interview will be performed 3, 12 and 24 months after discharge from hospital

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Urinary sample retrieved for biological assessment and biobanking
Description: Urinary sample collection will be performed within 72 hours of admission and before discharge from hospital

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: jugular and renal ultrasound (optional)
Description: optional jugular and renal ultrasound performed within 72hours of admission and before discharge from hospital
Study: NCT01402193

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pre-radiotherapy commencement of Arimidex
Description: Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Post radiotherapy commencement of Arimidex
Description: Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
Study: NCT03916692

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Carbohydrate drink
Description: Meal replacement drink containing 200 kcal

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Energy smart Carbohydrate blend
Description: Carbohydrate blend drink designed for low glycemic responses containing 200 kcal
Study: NCT02098343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
Description: Intravenous infusion.
Study: NCT02329405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03916692

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Liquid Dextrose
Description: Liquid Dextrose drink of 200 kcal
Study: NCT01179191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: morphine sulfate and naltrexone hydrochloride (EMBEDA)
Description: Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
Study: NCT02283528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Hybrid
Description: Place Hybrid arch bars

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erich
Description: Control group is Erich arch bars
Study: NCT04279431

Intervention type: DEVICE
Intervention: EEG Recording
Description: EEG recording acquired on BrainScope One device.

Intervention type: DEVICE
Intervention: EEG Recording
Description: EEG recording acquired on BrainScope One device.

Intervention type: OTHER
Intervention: Neurocognitive Tests
Description: Cognitive performance tests performed on BrainScope One device.

Intervention type: OTHER
Intervention: Neurocognitive Tests
Description: Cognitive performance tests performed on BrainScope One device.

Intervention type: OTHER
Intervention: Clinician Evaluation
Description: Clinician evaluation performed as part of standard of care at the clinical site.

Intervention type: OTHER
Intervention: Clinician Evaluation
Description: Clinician evaluation performed as part of standard of care at the clinical site.

Intervention type: OTHER
Intervention: 22-item CSI
Description: Self assessed 22-item Concussion Symptom Inventory (CSI).

Intervention type: OTHER
Intervention: 22-item CSI
Description: Self assessed 22-item Concussion Symptom Inventory (CSI).
Study: NCT00920439

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PoliorixTM
Description: Single dose, intramuscular administration.